targeting either the ligands or the receptor are currently in clinical development. However, a recent study showed that resistance emerges in response to sustained CSF-1R blockade therapy in certain cancer types. These effects remain unexplored in castration resistance prostate cancer (CRPC). In the present study, we evaluated the hypothesis that sustained CSF-1R blockade therapy induces therapeutic resistance in CRPC cells. Moreover, in one of our recent studies, we demonstrated the role of increased nitric oxide (NO) in reducing tumor burden in murine models for CRPC. Molecular events showed that NO impacts the TME and macrophage differentiation through suppression of Interleukin 34 (IL-34), which is also a ligand for CSF1 receptor (CSF1R). Therefore, as a next step we explored the hypothesis that combinatorial GSNO-CSF1R inhibitor therapy suppresses tumor growth and resistance development in CRPC.
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METHODS: GW2580, a CSF1-receptor inhibitor which is a key regulator in macrophage differentiation was tested in-vitro(22RV1 cells) and in-vivo(CRPC murine models-castrated SCID mice xenografted with 22RV1 cells), singularly and in combination with S-Nitrosoglutathione (GSNO) (an active NO donor). In-vivo dosage of 40mg/kg/day was used for GW2580 and 10mg/kg/day for GSNO were considered to evaluate the efficacy of CSF1R-inhibition, and CSF1R-inhibition in presence of increased NO levels on tumor burden and resistance development in CRPC.
RESULTS: Phosphatidylinositol 3-kinase (PI3K) pathway activity has been associated with resistance towards CSF1R inhibition therapy (GW2580) which is regulated by macrophage-derived growth factors. We found that PI3K signaling markers were significantly increased when CSF1R inhibition therapy is given to 22RV1 cells although GW2580 was able to suppress 22Rv1 cell proliferation in androgen deprived conditions. Additionally, levels of androgen receptor and its variants (markers largely studied for resistance development in CRPC) were induced upon CSF1R inhibition, thus suggesting towards possibility of resistance development. Importantly, in the presence of increased NO levels, CSF1R inhibition was able to show its cell proliferation capabilities without inducing P13K signaling pathway or AR, ARV7 levels. Furthermore, we investigated the impact of the combination GSNO-CSF1R inhibition therapy in in-vivo. Results validated the findings that P13K signaling, AR and ARV7 levels were induced upon CSF1R inhibition therapy and were reduced when CSF1R is inhibited in the presence of increased NO levels. Moreover, we evaluated macrophage infiltration, profiled cytokines and performed functional assays to establish the significance of combinational therapy of CSF1R inhibition and increased NO levels. CONCLUSIONS: Our findings suggest a critical role of increased nitric oxide levels on safe and specific action of CSF1R inhibition therapy for castration resistance prostate cancer. These results demonstrate that NO has the potential to enhance the therapeutic effects of CSF1R inhibition by averting resistance development. The small molecule anti-androgen, enzalutamide, is used to treat CRPC. However, expression of the AR-V7 splice variant impairs enzalutamide activity. A fluorescent-DHT surrogate, DHT-coumarin-1 (DHT-C-1), was one of many fluorescent-androgen surrogates synthesized to track androgen metabolism in CaP models. DHT-C-1, unexpectedly, inhibited growth of AR positive and AR-V7 positive CaP cell lines. The objective of these studies was to characterize DHT-C-1 activity in AR and AR-V7 positive and AR negative CaP cell lines.
METHODS: Androgen sensitive and AR-positive LAPC-4, VCaP and LNCaP, castration-recurrent AR and AR-V7 positive CWR-R1 and 22rv1, and androgen-independent and AR negative PC-3 and DU145 cell lines were treated with serum-free complete media (to simulate androgen deprivation), coumarin alone, to show the fluorophore did not impair CaP cell growth or AR signaling, DHT or DHT-C-1. PC-3 cells that stably expressed AR-green fluorescent protein (AR-GFP) were used for ImageStream analysis. ImageStream, a hybrid technique of flow cytometry and fluorescent-microscopy, was used to assess CaP cell uptake of DHT-C-1. MTT was used to assess cell growth and quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess kallikrein-related peptidase 2 (KLK2) and prostate-specific antigen (PSA) transcript abundance levels.
RESULTS is overexpressed in virtually all types of cancers including prostate cancer (PCa). We have previously reported that the androgen receptor (AR) induces miR-21 expression, and that elevated miR-21 is sufficient to drive PCa growth and castration resistance. However, the role of miR-21 in PCa initiation and progression has not been fully elucidated. To determine if the absence of miR-21 inhibits or delays prostate cancer incidence or progression, we crossed miR-21 KO mice with Hi-Myc mice. In this study, we identify that loss of miR-21 Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e83
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